Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus

Kymera Therapeutics, Inc. (KYMR) reported a loss of 58 cents per share in the second quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 69 cents. In the year-ago quarter, Kymera reported a loss of 67 cents per share. Loss narrowed in the quarter due to higher revenues. Collaboration revenues totaled $25.6 million, which beat the Zacks Consensus Estimate of$12 million. The reported figure increased 55.3% from the year-ago quarter's level. Collaboration revenues in the second quarter we ...